Wasatch Advisors LP Trims Stock Position in AtriCure, Inc. (NASDAQ:ATRC)

Wasatch Advisors LP decreased its holdings in AtriCure, Inc. (NASDAQ:ATRC) by 21.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 607,364 shares of the medical device company’s stock after selling 161,888 shares during the quarter. Wasatch Advisors LP owned 1.25% of AtriCure worth $18,561,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. Blue Trust Inc. raised its position in AtriCure by 1.8% in the fourth quarter. Blue Trust Inc. now owns 14,751 shares of the medical device company’s stock worth $414,000 after acquiring an additional 265 shares during the period. Invesco Ltd. raised its holdings in AtriCure by 0.8% in the 4th quarter. Invesco Ltd. now owns 43,647 shares of the medical device company’s stock worth $1,334,000 after purchasing an additional 334 shares during the period. Perkins Capital Management Inc. raised its holdings in AtriCure by 1.3% in the 4th quarter. Perkins Capital Management Inc. now owns 30,350 shares of the medical device company’s stock worth $927,000 after purchasing an additional 400 shares during the period. Truist Financial Corp lifted its position in AtriCure by 2.6% during the fourth quarter. Truist Financial Corp now owns 15,717 shares of the medical device company’s stock valued at $480,000 after purchasing an additional 403 shares in the last quarter. Finally, Franklin Resources Inc. grew its holdings in AtriCure by 0.9% during the third quarter. Franklin Resources Inc. now owns 56,843 shares of the medical device company’s stock valued at $1,569,000 after purchasing an additional 484 shares during the period. 99.11% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Karen Prange sold 6,100 shares of the business’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total value of $232,532.00. Following the sale, the director now owns 17,828 shares in the company, valued at approximately $679,603.36. The trade was a 25.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 3.20% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ATRC. Oppenheimer lifted their price objective on AtriCure from $36.00 to $45.00 and gave the company an “outperform” rating in a research report on Thursday, February 13th. Stifel Nicolaus upped their price target on shares of AtriCure from $36.00 to $48.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Canaccord Genuity Group decreased their price objective on shares of AtriCure from $66.00 to $52.00 and set a “buy” rating on the stock in a research report on Friday, March 28th. JPMorgan Chase & Co. dropped their target price on shares of AtriCure from $51.00 to $46.00 and set an “overweight” rating for the company in a report on Thursday, March 27th. Finally, BTIG Research reiterated a “buy” rating on shares of AtriCure in a research note on Thursday, March 27th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $49.44.

AtriCure Stock Down 0.9 %

Shares of ATRC stock opened at $32.08 on Thursday. The stock has a market cap of $1.57 billion, a P/E ratio of -33.77 and a beta of 1.65. The company’s fifty day simple moving average is $35.49 and its two-hundred day simple moving average is $34.31. The company has a quick ratio of 2.62, a current ratio of 3.65 and a debt-to-equity ratio of 0.13. AtriCure, Inc. has a 52 week low of $18.94 and a 52 week high of $43.11.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.